âš« Powered with Sitagliptin which is a FDA approved DDP-IV inhibitor that increases insulin release and decreases glucagen level in blood
âš« Sitagliptin and Metformin provided substantil and additive glycemic improvement and was generally well tolerated in patients
âš« Provides substantial and sustained Glycemic improvements and are well-tolerated
âš« Sitagliptin alone and in combination with Metformin for more than 6 months has improved body weight and body mass index reduction.